$11.750
+0.112 (+0.95%)收盘时
LMRI 资讯
LMRI 事件
Company Adjusts FY26 Revenue Outlook to $1.05B-$1.1B
Backs FY26 revenue view $1.05B-$1.1B, consensus $1.07B. Narrows FY26 adjusted EBITDA view to $235M-$241M from $234M-$242M.
Lumexa Imaging Reports Q2 Revenue of $264.16M
Reports Q2 revenue $264.16M, consensus $263.12M. "During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers," said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. "Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery, a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months."
Lumexa Imaging Forms Strategic Joint Venture with Hospital for Special Surgery
Lumexa Imaging announced the formation of a strategic joint venture with Hospital for Special Surgery. The collaboration represents Lumexa Imaging's ninth joint venture. Lumexa Imaging and HSS plan to expand access to advanced outpatient imaging services across the New York City metro area.
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Lumexa Imaging announced the appointment of Kyle Lynch as its new Chief Growth Officer, CGO. Lynch joins the executive leadership team to lead the company's enterprise growth strategy, with responsibility for expanding Lumexa Imaging's platform through joint ventures, acquisitions, and de novo development. Prior to joining Lumexa Imaging, Lynch served as SVP of Strategy and Development at SCA Health
Lumexa Imaging Holdings Inc Trading Resumes
Lumexa Imaging Holdings Inc trading resumes
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。